Tiger Brokers

维立志博-B(09887.HK)：维利信®(奥帕替苏米单抗，PD-L1/4–1BB双特异性抗体)联合用药治疗转移性结直肠癌的IB/II期临床试验首例患者入组

智通财经
Oct 16
【维立志博-B(09887.HK)：维利信®(奥帕替苏米单抗，PD-L1/4–1BB双特异性抗体)联合用药治疗转移性结直肠癌的IB/II期临床试验首例患者入组】智通财经APP讯，维立志博-B(09887.HK)发布公告，本公司欣然宣布，评估集团自主研发的维利信®(奥帕替苏米单抗，PD-L1/4–1BB 双特异性抗体)联合用药治疗转移性结直肠癌(mCRC)的开放、多中心Ib/II期临床试验完成首例患者入组。此标志着本公司以维利信®靶向免疫“冷肿瘤”的策略，由肺外神经内分泌癌(“EP-NEC”)、 胆道癌(“ BTC”)、 肝细胞癌(“ HCC”)及铂耐药卵巢癌(“PROC”)再作进一步延伸。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10